We validated a rat model of oxaliplatin-evoked motor neuropathy. Wire suspension and balance beam tests showed motor deficit in OXAL-treated rats. Motor fiber conductance velocity was reduced in OXAL-treated rats. OXAL-treatment increased the compound muscle action potential duration. Allopregnanolone treatment successfully corrected OXAL-evoked motor dysfunctions.